Revolution Medicines Inc (RVMD NASDAQ) stock market data APIs
$151.8728
-3.59(-2.4%)
as of May 6, 2026
Try our APIs with
free plan!
Revolution Medicines Inc Financial Data Overview
Price chart is built with
Anychart
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
151.8728
Open
148.2847
High
152.4136
Low
144.8132
52 wk Range
34-155.7
Market Cap
31 296 M
Shares Outstanding
213 M
Revenue
742 K
EPS
0
Beta
1.413
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Revolution Medicines Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Revolution Medicines Inc data using free add-ons & libraries
Get Revolution Medicines Inc Fundamental Data
Revolution Medicines Inc Fundamental data includes:
- Net Revenue: 742 K
- EBITDA: -1 174 619 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Revolution Medicines Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-11
- EPS/Forecast: -1.64
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Revolution Medicines Inc News
New
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary p...
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presente...
How FDA Expanded Access for Daraxonrasib and Phase 3 Survival Data At Revolution Medicines (RVMD) Has Changed Its Investment Story
Revolution Medicines recently secured FDA clearance for an expanded access program for its investigational pancreatic cancer drug daraxonrasib, following Phase 3 trial data showing a statistically sig...
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
The first-quarter 2026 reporting cycle of the Medical sector is in full swing. The sector primarily comprises pharma/biotech and medical device companies. Many pharma giants, like AbbVie and Eli Lil...
Get Revolution Medicines Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
